Variational AI Releases Enki 4 for Drug Discovery
Variational AI releases Enki 4, a new foundation model for small-molecule drug discovery featuring an improved algorithm and scalable architecture. It increases pre-trained target coverage from 592 to 760 targets. Additional details about performance, benchmarks, training data, and deployment are not available in the truncated description.
Key Points
- 1Enki 4 release expands pre-trained target coverage from 592 to 760 targets for small-molecule discovery.
- 2Improved algorithm and architecture designed to scale likely increase applicability across more biological targets.
- 3Broader pre-training could accelerate hit identification, but performance and validation details are not provided.
Scoring Rationale
Domain-specific foundation model update expands pre-training coverage, making it relevant to drug-discovery ML practitioners; however, the truncated description lacks benchmarks, validation, and deployment details, limiting immediate technical assessment.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
